tophaceous [tə'feiʃəs]

tophaceous的基本解释

-

[医] 砂砾性的

与tophaceous相关的网络例句 [注：此内容来源于网络，仅供参考]

OBJECTIVE: To evaluate the short-term safety and outcome of 2 different experimental applications of rasburicase 0.2 mg/kg in patients with tophaceous gout not treatable by allopurinol.

目的：评价别嘌呤醇治疗无效的白垩性痛风患者应用拉布立酶0.2毫克/公斤的2个不同实验的短期的安全性和疗效。

These data show that HRUS may assist in the management of gout in two ways: first, by aiding in the diagnosis by identifying the sonographic features that may be representative of the disease, and, second, by allowing the early detection of erosive joint damage and/or tophaceous deposits even in clinically silent joints.

这些数据表明HRUS可能在两方面协助痛风的治疗：第一，通过确定可能代表疾病的超音波特征协助诊断，第二，允许糜烂关节损害和/或痛风石沉积物的早期检测，即使在临床沉默的关节上也是如此。

Tophaceous gout results from continued precipitation of sodium urate crystals during attacks of acute gout.

沙粒状痛风是由急性痛风发作期尿酸钠盐结晶继续析出引起。

Optimal treatment of gout requires both non-pharmacological and pharmacological modalities and should be tailored according to: specific risk factors (levels of serum urate, previous attacks, radiographic signs); clinical phase (acute/recurrent gout, intercritical gout, and chronic tophaceous gout); general risk factors (age, sex, obesity, alcohol consumption, urate elevating drugs, drug interactions and comorbidity).

痛风最佳治疗需药物和非药物治疗手段相联合，并根据以下情况调整：（1）特殊的危险因素（血尿酸水平，以前发作情况和放射线表现）；（2）临床阶段（急性/复发性痛风，发作间歇期痛风和慢性痛风石性痛风）；（3）一般危险因素（年龄、性别、肥胖、饮酒、增高尿酸药，药物相互作用和合并疾病）。

Specific risk factors (levels of serum urate, previous attacks, radiographic signs); clinical phase (acute/recurrent gout, intercritical gout, and chronic tophaceous gout); general risk factors (age, sex, obesity, alcohol consumption, urate elevating drugs, drug interactions and comorbidity).

痛风最佳治疗需药物和非药物治疗手段相联合，并根据以下情况调整：（1）特殊的危险因素（血尿酸水平，以前发作情况和放射线表现）；（2）临床阶段（急性/复发性痛风，发作间歇期痛风和慢性痛风石性痛风）；（3）一般危险因素（年龄、性别、肥胖、饮酒、增高尿酸药，药物相互作用和合并疾病）。